FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	urden								

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP hours per response: 0.5 or Section 30(h) of the Investment Company Act of 1940

1 Nome o	ad Addraga af	Departing Deveces*			2	Issue	r Name aı	nd Ticke	r or Trad	lina S	vmhol		5.5	elationshin o	f Reporting	n Perso	nn(s) to Issi	ier		
Name and Address of Reporting Person* Shukla Sanjay						2. Issuer Name and Ticker or Trading Symbol aTYR PHARMA INC [LIFE]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Shukla Sanjay											-			Directo			10% Ov			
						Date of Earliest Transaction (Month/Day/Year)							_	X Officer below)	Officer (give title below)		Other (s below)	specify		
(Last) (First) (Middle)						02/05/2020								President and CEO						
3545 JO	HN HOPKI	NS COURT, SU	ITE #250																	
							4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
(Street)													Line) X Form filed by One Reporting Person							
SAN DIEGO CA 92121													Form filed by More than One Reporting							
(City) (State) (Zip)				-									Person							
		Ta	ble I - Nor	n-Deri	ivativ	/e Se	curitie	s Aca	uired.	Disi	posed of	. or Ben	eficiall	v Owned						
1 Title of	Security (Inst			2. Tran			2A. Deen		3.		1	es Acquire		5. Amoui	nt of	6. Ow	nership	7. Nature of		
[Date (Month/Day/Year)		Execution Date,				Disposed Of (D) (Instr. 3, 4				s For		m: Direct or Indirect	Indirect Beneficial		
				((MOIIII/Day/Tear)		(Month/Day/Year)							Owned F	ollowing		str. 4)	Ownership		
									Code	v	Amount	(A) or (D)	Price	Transact	Transaction(s) (Instr. 3 and 4)			(Instr. 4)		
Common stock 02/06						/2020			M ⁽¹⁾		1,786	,786 A		2,0	2,036		D			
Common stock 02/					07/20	7/2020			S ⁽³⁾		745	D	\$4.0	3 1,2	1,291		D			
			Table II -	Deriv	ative	Sec	urities	Acqu	ired, D	ispo	sed of,	or Bene	ficially	Owned		!	'			
											onvertib									
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/)	ate, T	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercis Expiration Dat (Month/Day/Ye		e	7. Title an of Securit Underlyin Derivative (Instr. 3 ar	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
													Amount or		(Instr. 4)	(0)				
						.,	.	_	Date .		Expiration		Number of							
					Code	V	(A)	(D)	Exercisa	DIE	Date	Title	Shares							
Employee Stock Option (right to buy)	\$4.39	02/05/2020			A		39,327		(4)		02/05/2030	Common Stock	39,327	\$0.00	39,32	7	D			
Restricted Stock Unit	(2)	02/06/2020			M ⁽¹⁾			1,786	(5)		(5)	Common Stock	1,786	\$0.00	1,786	6	D			

Explanation of Responses:

- 1. Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 6, 2019.
- 2. Restricted stock units convert into common stock on a one-for-one basis.
- 3. Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 6, 2019.
- 4. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 5, 2020, such that this option will be fully exercisable on February 5, 2024. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.
- 5. The RSU grant vests as to one-half (1/2) of the total number of units on each one year anniversary of the grant commencing on February 6, 2020.

Remarks:

Nancy E. Denyes, attorney-in-02/07/2020 <u>fact</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.